Sanofi India Ltd

BSE
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

Start SIP in Sanofi India Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
38.87% Fall from 52W High
-23.9
TTM PE Ratio
Below industry Median
27
Price to Book Ratio
High in industry
14.6
Dividend yield 1yr %
High in industry
2.6
TTM PEG Ratio
RSI
RSI is mid-range
31.6
MFI
MFI is mid-range
45.6

Sanofi India Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Sanofi India Ltd shareholding Pattern

Promoter
60.4%
Foreign Institutions
6.1%
Mutual Funds
11.7%
Domestic Institutions
23.1%
Public
10.4%
Promoter
60.4%
Foreign Institutions
6.3%
Mutual Funds
11.5%
Domestic Institutions
21%
Public
12.3%
Promoter
60.4%
Foreign Institutions
6.8%
Mutual Funds
10%
Domestic Institutions
21.7%
Public
11.1%
Promoter
60.4%
Foreign Institutions
6.7%
Mutual Funds
9.6%
Domestic Institutions
19.6%
Public
13.2%
Promoter
60.4%
Foreign Institutions
6.7%
Mutual Funds
9.5%
Domestic Institutions
19.5%
Public
13.4%
Promoter
60.4%
Foreign Institutions
7%
Mutual Funds
9.4%
Domestic Institutions
19.2%
Public
13.4%

Sanofi India Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
6,467.30
10Day EMA
6,575.20
12Day EMA
6,639.30
20Day EMA
6,925.10
26Day EMA
7,114.60
50Day EMA
7,583.00
100Day EMA
7,901.30
200Day EMA
7,853.00
5Day SMA
6,471.50
10Day SMA
6,516.80
20Day SMA
6,675.50
30Day SMA
7,529.30
50Day SMA
7,930.90
100Day SMA
8,174.60
150Day SMA
8,240.20
200Day SMA
8,071.70
Delivery & Volume
Resistance & Support
6,435.45
Pivot
Resistance
First Resistance
6,470.55
Second Resistance
6,506.85
Third Resistance
6,541.95
Support
First Support
6,399.15
Second support
6,364.05
Third Support
6,327.75
Relative Strength Index
31.61
Money Flow Index
45.62
MACD
-475.33
MACD Signal
-496.07
Average True Range
287.01
Average Directional Index
28.94
Rate of Change (21)
-35.99
Rate of Change (125)
-23.42
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Alembic Pharmaceuticals Ltd.
19646.48
641.65
1093.05
AstraZeneca Pharma India Ltd.
17161.13
3650.05
7550
Wockhardt Ltd.
13625.84
213.25
993.35
Eris Lifesciences Ltd.
14087.17
686.35
1089.85
Piramal Pharma Ltd.
20098.34
87.55
166.6
Indegene Ltd.
14054.66
468.9
659.7

Sanofi India Ltd Company background

Founded in: 1956
Managing director: Rodolfo Hrosz
Sanofi India Limited, (Previously known as Aventis Pharma Limited), is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company offers a wide array of medicines for therapy areas such as Diabetes (both insulins, andoral medications), Cardiology, Thrombosis, Epilepsy, Allergies, Infections, Vitamins, Central Nervous System and Antihistamines. The products manufactured by the Company are distributed in India and exported to many developed as well as developing countries, including Germany, Australia, UK, Russia and Italy. Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The Company has its own manufacturing facility at Goa and Ankleshwar, Gujarat. It sells products through independent distributors primarily in India.Sanofi, one of the worlds leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.37% of its paidup share capital. The Company was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, the name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited, Aventis Pharma Limited and Sanofi India Limited.During the year 199798, the Joint Venture Company, Chiron Behring Vaccines Pvt Ltd started to manufacture antirabbies vaccine Rabipur. Roussel India Ltd was amalgamated with the Company with effect from April 1, 1997 and Hoechst Nepal (Pvt) Ltd, a subsidiary Company in Nepal was wound up during the year. During the year 19992000, Aventis launched antidiabetic Amaryl broad spectrum antiinfective Tavanic and line extension of antihypertensive Cardace H. In the year 2001, RhonePoulenc Rorer (India) Pvt Ltd was amalgamated with the company. The company name was changed from Hoechst Marion Roussel Ltd to Aventis Pharma Ltd with effect from July 11 2001. In July 2003. the company launched Lantus, the worlds first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.In the year 2004, the company came under the control of SanofiSynthelabo, now called sanofiaventis which acquired indirect control 50.1% of the companys paidup share capital. In the year 2006, the company completed the project for setting up additional facilities for manufacturing Combiflam Tablets in Ankleshwar, Gujarat.In the year 2007, the company launched Cardace H 10 mg as a comprehensive cardiovascular treatment option in hypertension at risk patients. In May 2007, the company launched a line extension, Amaryl M. A new granulation train dedicated for production of Combiflam tablets was installed in Ankleshwar. This product which was being manufactured partly in a toll manufacturing site is now planned to be manufactured entirely in Ankleshwar.In April 2008, the company launched a new prefilled diaposable insulin pen, SoloStar for use with the 24hour insulin Lantus. This disposable insulin pen is to be used for the treatment of hyperglycemia in people with type 1 or type 2 diabetes.On 13 December 2010, Aventis Pharma Ltd announced that it has agreed with its joint venture partner Novartis Vaccines Diagnosics Inc. to sell its 49% shareholding in Chiron Behring Vaccines Private Limited (CBVPL) to Novartis Pharma AG and exit the joint venture. The purchase price agreed to be paid is US Dollars 22.399 million. Simultaneously, Aventis Pharma has agreed to continue to provide certain utilities and services to the Ankleshwar plant of CBVPL for a period of three years from the date of closing on mutually terms. CBVPL manufactures the antirabies vaccine Rabipur at its plant in Ankleshwar, which was until February 2009 distributed in India by Aventis Pharma and is presently distributed by Novartis Healthcare Private Limited. On 27 December 2010, Aventis Pharma Ltd announced that it has completed the sale of its 49% shareholding in Chiron Behring Vaccines Private Limited to Novartis Pharma AG. The company received sale consideration of Rs 100.75 crore (equivalent to US Dollars 22.399 million).On 24 August 2011, Aventis Pharma Limited (part of the Sanofi Group) announced that it has entered into a definitive agreement to acquire Universal Medicare Private Limiteds business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies. It is expected to close in the fourth quarter of 2011, subject to certain conditions precedent. Universal Medicare, (headquartered in Mumbai, India) manufactures, markets and distributes branded nutraceutical formulations in India through their sales and marketing infrastructure. With this acquisition, Aventis Pharma will advance its sustainable growth strategy in India and facilitate the creation of a consumer healthcare and wellness platform.The Registrar of Companies approved the companys change of name from Aventis Pharma Limited to Sanofi India Limited with effect from 11 May 2012. The shareholders of the company had earlier approved the name change at the Annual General Meeting held on 3 May 2012. The decision to change the name of the Groups listed entity in India comes a year after the name of the parent company was changed globally from sanofiaventis to Sanofi in May 2011.On 9 October 2012, Sanofi India Limited announced the launch of AllStar, its first indigenously manufactured reusable insulin pen.On 14 February 2013, Sanofi India Limited announced the launch of Combiflam Plus, a targeted, fast and effective solution for headaches, which is also gentle on the stomach. A line extension of one of Sanofi Indias flagship brand Combiflam, the launch of this new product marks the companys foray into the OTC headache segment in India.On 11 November 2014, Sanofi India announced that its Board of Directors has approved of the company selling its commercial premises, being five floors and corresponding carparking spaces in the building known as Hoechst House situated at Nariman Point, Mumbai to Bright Star Investments Private Limited and its Group companies for a total consideration of Rs 134.25 crore.On 21 July 2015, Sanofi India announced that its Board of Directors has approved of the company selling its commercial property, being land and building at Andheri, Mumbai for a consideration of Rs 111 crore. The transaction is expected to be completed in the quarter ending 30 September 2015.In August 2017, the first OTC extension of the iconic brand Combiflam was launched in the topical pain care space with the name Combiflam Icy Hot.12 February 2018, Sanofi India announced the launch of its new insulin product Toujeo. Toujeo is a oncedaily, longacting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.In 2019, Sanofi launched Combiflam Plus (Paracetamol and Caffeine combination). Besides, two new brands were launched, DePura by Sanofi Cal. On 29th May 2020, the Company closed the transaction of slump sale and transfer of its Ankleshwar manufacturing facility toZentiva Private Limited. During the year 202122, the Companys Nutraceuticals business, was sold as a going concern basis to Universal Nutriscience Private Limited through Slump Sale for a consideration of Rs. 587 Crore, effective on September 30, 2021. In 2021, a unique Toustarr pen, dedicated cartridge system device was launched.
Read More

Sanofi India Ltd FAQs

The past 1-year return of Sanofi India Ltd [SANOFI] share was -7.11. The Sanofi India Ltd [SANOFI] share hit a 1-year low of Rs. 5850.55 and a 1-year high of Rs. 10526.05.

The Mutual Fund Shareholding was 11.67% at the end of .

You can easily buy Sanofi India Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -